Literature DB >> 3679904

Two forms of HLA class I molecules in human plasma.

M S Krangel1.   

Abstract

Soluble HLA-A,-B antigens have previously been detected in human plasma. More recently, these molecules have been demonstrated to be secreted in water soluble form by cell lines and peripheral blood lymphocytes in vitro due to RNA splicing events which delete exon five from a fraction of class I antigen transcripts. In order to determine whether plasma HLA-A,-B molecules arise by this mechanism, their biochemical properties are analyzed. Based upon molecular weight, detergent binding, and lipid binding properties, it was demonstrated that two forms of HLA-A,-B molecules are present in the plasma. A 43 kd form that binds both lipids and detergents is presumed to be a shed version of the membrane form. However, a 39 kd form that fails to bind lipids and detergents has properties identical to those molecules secreted in vitro. It is suggested that these molecules arise by alternative splicing events in vivo that are identical to those characterized in vitro. Although all tested individuals display shed and/or secreted plasma class I molecules, it is striking that HLA-A24 occurs in both a shed and a secreted form at levels higher than all other alleles examined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3679904     DOI: 10.1016/0198-8859(87)90029-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  13 in total

1.  Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

Authors:  F Puppo; F Torre; P Contini; M Ghio; S Brenci; R Brizzolara; N Sinelli; N Campo; F Indiveri; A Picciotto
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Quantification of soluble HLA class I gene products by an enzyme linked immunosorbent assay.

Authors:  I Doxiadis; U Westhoff; H Grosse-Wilde
Journal:  Blut       Date:  1989-11

Review 3.  Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.

Authors:  Irena Adamashvili; Roger E Kelley; Thomas Pressly; John C McDonald
Journal:  Rheumatol Int       Date:  2005-06-29       Impact factor: 2.631

Review 4.  Prospects for induction of tolerance in renal transplantation.

Authors:  A M Krensky; C Clayberger
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

5.  HLA-B27 determination using serological methods. A comparison of enzyme immunoassay and a microlymphocytotoxic test with flow cytometry and a molecular biological assay.

Authors:  A Dunky; J Neumüller; C Hübner; G F Fischer; P M Bayer; E Wagner; D W Schwartz; W R Mayr
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 6.  Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.

Authors:  Katerina Bakela; Irene Athanassakis
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

7.  Alternative splicing of class Ib major histocompatibility complex transcripts in vivo leads to the expression of soluble Qa-2 molecules in murine blood.

Authors:  P Tabaczewski; H Shirwan; K Lewis; I Stroynowski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

8.  Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma.

Authors:  J A Brieva; L M Villar; G Leoro; J C Alvarez-Cermeño; E Roldán; P Gonzalez-Porqué
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

9.  Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis.

Authors:  J Alvarez-Cermeño; J M Echevarría; L M Villar; I Lázaro; A Bootello; P González-Porque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-10       Impact factor: 10.154

10.  Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).

Authors:  W E Aulitzky; H Grosse-Wilde; U Westhoff; H Tilg; W Aulitzky; G Gastl; M Herold; C Huber
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.